Insulin Glargine (Biosimilar)
Diabetes
Approved/CommercialMarketed
Key Facts
About Gulf Pharmaceutical Industries
Gulf Pharmaceutical Industries, known as Julphar, is a publicly listed company on the Abu Dhabi Securities Exchange (ADX) with a mission to provide high-quality, affordable medicines to the MENA region and beyond. The company has established itself through a diversified portfolio spanning diabetes, cardiovascular, gastroenterology, and anti-infective therapeutic areas. Its strategic direction includes expanding its biosimilars pipeline and leveraging its extensive manufacturing and distribution network for regional growth.
View full company profileTherapeutic Areas
Other Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Toujeo | Sanofi | Commercial |
| Lantus | Sanofi | Commercial |
| Semglee (insulin glargine biosimilar) | Viatris | Approved |
| Semglee (Insulin Glargine) | Biocon | Approved |
| Insulin Aspart | Biocon | Phase 3 |
| Liraglutide | Biocon | Phase 3 |
| MK-1293 (insulin glargine biosimilar) | Organon | Approved/Filed |
| CYAPO913 | FibroBiologics | Discovery |